Co-Authors
This is a "connection" page, showing publications co-authored by Alessandra Oliva and Mario Venditti.
Connection Strength
3.413
-
Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission. Infection. 2021 Oct; 49(5):965-975.
Score: 0.947
-
Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature. Infection. 2020 Dec; 48(6):871-877.
Score: 0.895
-
Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection. 2022 Feb; 50(1):83-92.
Score: 0.238
-
Low-Grade Endotoxemia and Thrombosis in COVID-19. Clin Transl Gastroenterol. 2021 06 04; 12(6):e00348.
Score: 0.237
-
The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). J Med Virol. 2021 Jul; 93(7):4319-4325.
Score: 0.234
-
Monocyte absolute count as a preliminary tool to distinguish between SARS-CoV-2 and influenza A/B infections in patients requiring hospitalization. Infez Med. 2020 Dec 01; 28(4):534-538.
Score: 0.229
-
Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent. Eur J Clin Invest. 2021 Jan; 51(1):e13418.
Score: 0.227
-
Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia. New Microbiol. 2017 Jul; 40(3):205-207.
Score: 0.181
-
Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Diagn Microbiol Infect Dis. 2021 Jun; 100(2):115347.
Score: 0.058
-
Nox2 activation in Covid-19. Redox Biol. 2020 09; 36:101655.
Score: 0.056
-
Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circ Res. 2020 07 17; 127(3):400-401.
Score: 0.055
-
Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int J Antimicrob Agents. 2020 Aug; 56(2):106029.
Score: 0.055